 Melanoma tumor vaccine five-year follow-up many years various melanoma vaccines unique melanoma vaccine subcellular tumor homogenate adjuvants vaccine stage stage II melanoma patients years survival rates Sixty-four stage males stage survival rates difference lymph node dissection Thirty-six stage II males stage II females survival rates stage II patients positive node positive nodes positive nodes survival rates published series historical controls significant differences stage II patients positive nodes positive nodes significant increase survival stage II patients high risk recurrence tumor homogenate vaccine vaccine warrants analysis development use phase III clinical trial